Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Abstract Background We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis (AS) and non-radiographic axial spondyloarth...

Full description

Bibliographic Details
Main Authors: Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Arthritis Research & Therapy
Subjects:
Ixekizumab
Psoriasis
Psoriatic arthritis
Axial Spondyloarthritis
Long-term Safety
Integrated Safety
Online Access:https://doi.org/10.1186/s13075-023-03257-7

Internet

https://doi.org/10.1186/s13075-023-03257-7

Similar Items